Search

Home > Diabetes Knowledge into Practice Podcast > Newsflash | VERTIS CV analysis: Ertugliflozin outcomes by baseline metformin use
Podcast: Diabetes Knowledge into Practice Podcast
Episode:

Newsflash | VERTIS CV analysis: Ertugliflozin outcomes by baseline metformin use
Category: Health
Duration: 00:04:14
Publish Date: 2021-09-09 16:25:41
Description:

In another news episode, hear a 5-minute summary of the VERTIS CV post hoc analysis presented at ESC 2021. VERTIS CV was the the cardiovascular outcomes trial investigating the SGLT2 inhibitor ertugliflozin in people with type 2 diabetes and cardiovascular disease; this latest analysis looked at whether the effects of ertugliflozin on cardiovascular and renal outcomes varied according to baseline metformin use. Listen for a quick overview of the key findings.

Abstract: Cosentino F, et al. Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial. Eur Heart J 2021. In press

For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn.

Funding statement:

This independent educational activity is supported by educational grants from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.
Total Play: 0